Lifelong genetically lowered sclerostin and risk of cardiovascular disease

Схожие документы

• Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
  по: Bovijn, J, и др.
  Опубликовано: (2020)
• Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”
  по: Bovijn, J, и др.
  Опубликовано: (2021)
• Causal relevance of obesity on the leading causes of death in women and men: A Mendelian randomization study
  по: Censin, JC, и др.
  Опубликовано: (2019)
• Causal relationships between obesity and the leading causes of death in women and men
  по: Censin, JC, и др.
  Опубликовано: (2019)
• Commentary: Mendelian randomization and women's health
  по: Censin, JC, и др.
  Опубликовано: (2019)